BRD4 and acute myeloid leukemia: These compounds have demonstrated impressive pre-clinical efficacy in a variety of cancer models, including BRD4–NUT fusions NUT-midline carcinoma (NMC), acute myeloid leukemia (AML), medulloblastoma, breast cancer, and lung cancer [39,40,41].